Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.17
PATH's Cash to Debt is ranked higher than
57% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. PATH: 1.17 )
PATH' s 10-Year Cash to Debt Range
Min: 0.16   Max: No Debt
Current: 1.17

F-Score: 2
Z-Score: -5.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -814.27
PATH's ROE (%) is ranked lower than
53% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. PATH: -814.27 )
PATH' s 10-Year ROE (%) Range
Min: -814.27   Max: -71.08
Current: -814.27

-814.27
-71.08
ROA (%) -80.16
PATH's ROA (%) is ranked higher than
54% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. PATH: -80.16 )
PATH' s 10-Year ROA (%) Range
Min: -311.24   Max: -55.67
Current: -80.16

-311.24
-55.67
ROC (Joel Greenblatt) (%) -3620.14
PATH's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. PATH: -3620.14 )
PATH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21618.37   Max: -3620.14
Current: -3620.14

-21618.37
-3620.14
» PATH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

PATH Guru Trades in

Q2 2013

PATH Guru Trades in Q2 2013

Ronald Muhlenkamp 11,000 sh (New)
Jim Simons 17,017 sh (New)
» More
Q3 2013

PATH Guru Trades in Q3 2013

Jim Simons 70,464 sh (+314.08%)
Ronald Muhlenkamp 20,560 sh (+86.91%)
» More
Q4 2013

PATH Guru Trades in Q4 2013

Mario Gabelli 114,500 sh (New)
Jim Simons 121,900 sh (+73%)
Ronald Muhlenkamp 20,425 sh (-0.66%)
» More
» Details

Insider Trades

Latest Guru Trades with PATH

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2013-12-31 New Buy$1.62 - $3.39 $ 4.2592%114500
Ronald Muhlenkamp 2013-09-30 Add 86.91%$2.39 - $2.91 $ 4.2559%20560
Ronald Muhlenkamp 2013-06-30 New Buy0.01%$2.67 - $3.66 $ 4.2532%11000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 18.48
PATH's P/B is ranked lower than
72% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. PATH: 18.48 )
PATH' s 10-Year P/B Range
Min: 0.72   Max: 3.92
Current: 18.48

0.72
3.92
EV-to-EBIT -6.69
PATH's EV-to-EBIT is ranked lower than
120% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. PATH: -6.69 )
PATH' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -6.69

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 18.48
PATH's Price/Tangible Book is ranked lower than
81% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. PATH: 18.48 )
PATH' s 10-Year Price/Tangible Book Range
Min: 1.64   Max: 44.78
Current: 18.48

1.64
44.78
Forward Rate of Return (Yacktman) -412.63
PATH's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. PATH: -412.63 )
PATH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -412.63

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:QNP.Germany
NuPathe Inc., a Delaware corporation was incorporated in January 2005. It is a biopharmaceutical company develops and commercializes branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The Company's lead product, Zecuity (sumatriptan iontophoretic transdermal system), was approved by the FDA on January 17, 2013 for the acute treatment of migraine, with or without aura, in adults. In addition to Zecuity, it has two pipeline product candidates, NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder use its proprietary LAD biodegradable implant technology. Zecuity is a single-use, battery-powered patch that actively delivers sumatriptan, the prescribed migraine medication in the U.S., through the skin. Zecuity is the first patch approved by the FDA for the acute treatment of migraine. It expects to make Zecuity available by prescription in the fourth quarter of 2013 and is actively seeking partnerships to maximize the commercial potential for Zecuity in the U.S. and territories throughout the world. Zecuity is designed to overcome limitations of current migraine treatments that are related to route of administration and peak plasma concentrations, and in particular, to address the unmet needs of patients who experience migraine-related nausea (MRN) as part of their attacks. Both of its pipeline product candidates, NP201 and NP202, are designed to deliver therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes ropinirole, an FDA-approved dopamine agonist, and is designed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is designed to help address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an FDA-approved atypical antipsychotic. Its major competitors include organizations such as major multinational pharmaceutical companies, established biotechnology companies and specialty pharmaceutical and generic drug companies. Prescription drug products are subject to extensive pre- and post-market regulation by the FDA, including regulations that govern the testing, manufacturing, distribution, safety, efficacy, approval, labeling, storage, record keeping, reporting, advertising and promotion of such products under the FDCA, and its implementing regulations, and by comparable agencies and laws in foreign countries.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide